These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28779138)

  • 1. Glargine and degludec: Solution behaviour of higher dose synthetic insulins.
    Adams GG; Alzahrani Q; Jiwani SI; Meal A; Morgan PS; Coffey F; Kok S; Rowe AJ; Harding SE; Chayen N; Gillis RB
    Sci Rep; 2017 Aug; 7(1):7287. PubMed ID: 28779138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
    Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
    Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
    Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrated insulin glargine (Toujeo) for diabetes.
    Med Lett Drugs Ther; 2015 May; 57(1468):69-70. PubMed ID: 25941955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
    Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
    J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study.
    Lualdi C; Silverii A; Dicembrini I; Pala L; Monami M; Mannucci E
    J Endocrinol Invest; 2019 Mar; 42(3):319-326. PubMed ID: 29987755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.
    Havelund S; Ribel U; Hubálek F; Hoeg-Jensen T; Wahlund PO; Jonassen I
    Pharm Res; 2015 Jul; 32(7):2250-8. PubMed ID: 25563978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes.
    Oya J; Nakagami T; Hasegawa Y; Katamine A; Kondo Y; Babazono T
    J Diabetes Investig; 2021 Nov; 12(11):1983-1991. PubMed ID: 33938149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the Next Generation of Long-Acting Basal Insulins: Insulin Degludec and Insulin Glargine.
    Stailey M; Conway SE
    Consult Pharm; 2017 Jan; 32(1):42-46. PubMed ID: 28077204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.
    Freemantle N; Meneghini L; Christensen T; Wolden ML; Jendle J; Ratner R
    Diabet Med; 2013 Feb; 30(2):226-32. PubMed ID: 23199058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glargine versus insulin degludec in patients failing on oral therapy in type 2 diabetes: A retrospective real world comparative data from India.
    Ghosal S; Sinha B; Gangopadhyay KK
    Diabetes Metab Syndr; 2016; 10(3):161-5. PubMed ID: 26822462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.
    Home PD; Meneghini L; Wendisch U; Ratner RE; Johansen T; Christensen TE; Jendle J; Roberts AP; Birkeland KI
    Diabet Med; 2012 Jun; 29(6):716-20. PubMed ID: 22150786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study.
    Jensen MH; Hejlesen O; Vestergaard P
    Diabetes Metab Res Rev; 2020 Jan; 36(1):e3225. PubMed ID: 31647163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?
    Hood RC
    Diabetes Technol Ther; 2017 Apr; 19(4):203-205. PubMed ID: 28418731
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
    Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
    Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
    Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.